Prostate cancer, the most common cancer in men, progresses from an androgen-dependent to a castration-resistant state driven by androgen receptor (AR) alterations, leading to treatment resistance often enhanced by epigenetic changes and tumor microenvironment interactions [61]. This evidence concerns the gene AR and prostate carcinoma.